2026 Q2 - tulosraportti
85 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 000 | ||
| 10 000 | ||
| 10 000 | ||
| 10 000 | ||
| 10 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 13.11.2025 | ||
2025 Q2 - tulosraportti 14.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenAI generert analyse som ikke nødvendigvis representerer mine vurderinger. What the Portsmouth Delay Tells Us About Future Pace The delay in moving from a successful pilot to a commercial subscription contract at Portsmouth reveals three major structural hurdles in the NHS that Induct is currently trying to solve: 1. Validation of Clinical Data ≠ Commercial Readiness: A pilot with AstraZeneca can easily prove that the software helps patients or saves clinicians time (clinical validation). However, it does not solve the commercial validation. The NHS requires intense scrutiny over data governance (IG), compliance with DTAC (Digital Technology Assessment Criteria), liability insurance, and long-term funding sustainability before a hospital can legally sign a commercial subscription. 2. The "Pilotitis" Epidemic: The NHS is famous for running pilots funded by third parties (like pharma companies) that struggle to transition into core hospital budgets once the pilot funding ends. Induct is currently fighting to transition from an "innovation project" into a permanent "line-item expense" for Portsmouth. 3. The First Contract is Always the Hardest: Because Induct historically used an advertising-funded model, they are building a brand-new subscription framework from scratch. Portsmouth is essentially acting as the guinea pig for this legal contract. The Pace Going Forward: For any completely new hospital networks where Induct has no footprint, the pace will remain slow (12 to 18 months per contract) if they start from scratch. However, if Induct successfully finalizes the Portsmouth contract, the pace for their existing pipeline (like Hull) should speed up significantly because they can reuse the exact same legal and data compliance blueprint. When Will We See Mass Deployment? Realistically, mass deployment of Induct's platform will not happen before late 2027 or early 2028. The rollout is expected to follow a specific three-phase timeline based on the current NHS and RTP program constraints: Phase 1: Present - Mid 2027] --> [Phase 2: Mid 2027 - Late 2027] --> [Phase 3: 2028+] Portsmouth & Pipeline Blueprint RTP Spending Spike Adoption True Mass Deployment • Phase 1: The Blueprint Phase (Present to Mid-2027) • What to expect: Induct must first close the Portsmouth subscription and use that exact framework to sign 1 or 2 pipeline networks (like Hull) that they are already in discussions with. • Phase 2: The RTP Spending Spike (Mid-2027 to December 2027) • What to expect: This is when the RTP program faces its "use it or lose it" budget deadline. If AstraZeneca successfully positions Induct’s severe asthma pathway as a pre-validated, "ready-to-plug-in" solution, regional Integrated Care Boards (ICBs) looking to rapidly spend their remaining RTP allocations will buy into Induct's pre-negotiated contract framework. This will look like a cluster of 5 to 10 regional networks adopting the platform within a short window. • Phase 3: True Mass Deployment (2028 and Beyond) • What to expect: True mass deployment across dozens of NHS trusts will only happen once the platform is adopted at the ICB (Integrated Care Board) level, rather than hospital by hospital. Once an ICB buys a license, the software is deployed across an entire region simultaneously. The Shareholder Takeaway The slow pace at Portsmouth is not necessarily a sign of failure, but a sign of the grueling administrative reality of the NHS. The true test of Induct's management is whether they can finalize the Portsmouth deal before the Spring 2027 RTP funding window opens. If they miss that window, they risk missing the wave of accelerated cash deployment before the RTP program ends in December 2027.
·2 päivää sitten-98.68% overall I am selling out and taking my loss, all trust in this company is gone Watch out out there with falling knives especially this one
·26.10.How are you?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
85 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenAI generert analyse som ikke nødvendigvis representerer mine vurderinger. What the Portsmouth Delay Tells Us About Future Pace The delay in moving from a successful pilot to a commercial subscription contract at Portsmouth reveals three major structural hurdles in the NHS that Induct is currently trying to solve: 1. Validation of Clinical Data ≠ Commercial Readiness: A pilot with AstraZeneca can easily prove that the software helps patients or saves clinicians time (clinical validation). However, it does not solve the commercial validation. The NHS requires intense scrutiny over data governance (IG), compliance with DTAC (Digital Technology Assessment Criteria), liability insurance, and long-term funding sustainability before a hospital can legally sign a commercial subscription. 2. The "Pilotitis" Epidemic: The NHS is famous for running pilots funded by third parties (like pharma companies) that struggle to transition into core hospital budgets once the pilot funding ends. Induct is currently fighting to transition from an "innovation project" into a permanent "line-item expense" for Portsmouth. 3. The First Contract is Always the Hardest: Because Induct historically used an advertising-funded model, they are building a brand-new subscription framework from scratch. Portsmouth is essentially acting as the guinea pig for this legal contract. The Pace Going Forward: For any completely new hospital networks where Induct has no footprint, the pace will remain slow (12 to 18 months per contract) if they start from scratch. However, if Induct successfully finalizes the Portsmouth contract, the pace for their existing pipeline (like Hull) should speed up significantly because they can reuse the exact same legal and data compliance blueprint. When Will We See Mass Deployment? Realistically, mass deployment of Induct's platform will not happen before late 2027 or early 2028. The rollout is expected to follow a specific three-phase timeline based on the current NHS and RTP program constraints: Phase 1: Present - Mid 2027] --> [Phase 2: Mid 2027 - Late 2027] --> [Phase 3: 2028+] Portsmouth & Pipeline Blueprint RTP Spending Spike Adoption True Mass Deployment • Phase 1: The Blueprint Phase (Present to Mid-2027) • What to expect: Induct must first close the Portsmouth subscription and use that exact framework to sign 1 or 2 pipeline networks (like Hull) that they are already in discussions with. • Phase 2: The RTP Spending Spike (Mid-2027 to December 2027) • What to expect: This is when the RTP program faces its "use it or lose it" budget deadline. If AstraZeneca successfully positions Induct’s severe asthma pathway as a pre-validated, "ready-to-plug-in" solution, regional Integrated Care Boards (ICBs) looking to rapidly spend their remaining RTP allocations will buy into Induct's pre-negotiated contract framework. This will look like a cluster of 5 to 10 regional networks adopting the platform within a short window. • Phase 3: True Mass Deployment (2028 and Beyond) • What to expect: True mass deployment across dozens of NHS trusts will only happen once the platform is adopted at the ICB (Integrated Care Board) level, rather than hospital by hospital. Once an ICB buys a license, the software is deployed across an entire region simultaneously. The Shareholder Takeaway The slow pace at Portsmouth is not necessarily a sign of failure, but a sign of the grueling administrative reality of the NHS. The true test of Induct's management is whether they can finalize the Portsmouth deal before the Spring 2027 RTP funding window opens. If they miss that window, they risk missing the wave of accelerated cash deployment before the RTP program ends in December 2027.
- ·2 päivää sitten-98.68% overall I am selling out and taking my loss, all trust in this company is gone Watch out out there with falling knives especially this one
- ·26.10.How are you?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 000 | ||
| 10 000 | ||
| 10 000 | ||
| 10 000 | ||
| 10 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 13.11.2025 | ||
2025 Q2 - tulosraportti 14.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
85 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 12.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 13.11.2025 | ||
2025 Q2 - tulosraportti 14.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenAI generert analyse som ikke nødvendigvis representerer mine vurderinger. What the Portsmouth Delay Tells Us About Future Pace The delay in moving from a successful pilot to a commercial subscription contract at Portsmouth reveals three major structural hurdles in the NHS that Induct is currently trying to solve: 1. Validation of Clinical Data ≠ Commercial Readiness: A pilot with AstraZeneca can easily prove that the software helps patients or saves clinicians time (clinical validation). However, it does not solve the commercial validation. The NHS requires intense scrutiny over data governance (IG), compliance with DTAC (Digital Technology Assessment Criteria), liability insurance, and long-term funding sustainability before a hospital can legally sign a commercial subscription. 2. The "Pilotitis" Epidemic: The NHS is famous for running pilots funded by third parties (like pharma companies) that struggle to transition into core hospital budgets once the pilot funding ends. Induct is currently fighting to transition from an "innovation project" into a permanent "line-item expense" for Portsmouth. 3. The First Contract is Always the Hardest: Because Induct historically used an advertising-funded model, they are building a brand-new subscription framework from scratch. Portsmouth is essentially acting as the guinea pig for this legal contract. The Pace Going Forward: For any completely new hospital networks where Induct has no footprint, the pace will remain slow (12 to 18 months per contract) if they start from scratch. However, if Induct successfully finalizes the Portsmouth contract, the pace for their existing pipeline (like Hull) should speed up significantly because they can reuse the exact same legal and data compliance blueprint. When Will We See Mass Deployment? Realistically, mass deployment of Induct's platform will not happen before late 2027 or early 2028. The rollout is expected to follow a specific three-phase timeline based on the current NHS and RTP program constraints: Phase 1: Present - Mid 2027] --> [Phase 2: Mid 2027 - Late 2027] --> [Phase 3: 2028+] Portsmouth & Pipeline Blueprint RTP Spending Spike Adoption True Mass Deployment • Phase 1: The Blueprint Phase (Present to Mid-2027) • What to expect: Induct must first close the Portsmouth subscription and use that exact framework to sign 1 or 2 pipeline networks (like Hull) that they are already in discussions with. • Phase 2: The RTP Spending Spike (Mid-2027 to December 2027) • What to expect: This is when the RTP program faces its "use it or lose it" budget deadline. If AstraZeneca successfully positions Induct’s severe asthma pathway as a pre-validated, "ready-to-plug-in" solution, regional Integrated Care Boards (ICBs) looking to rapidly spend their remaining RTP allocations will buy into Induct's pre-negotiated contract framework. This will look like a cluster of 5 to 10 regional networks adopting the platform within a short window. • Phase 3: True Mass Deployment (2028 and Beyond) • What to expect: True mass deployment across dozens of NHS trusts will only happen once the platform is adopted at the ICB (Integrated Care Board) level, rather than hospital by hospital. Once an ICB buys a license, the software is deployed across an entire region simultaneously. The Shareholder Takeaway The slow pace at Portsmouth is not necessarily a sign of failure, but a sign of the grueling administrative reality of the NHS. The true test of Induct's management is whether they can finalize the Portsmouth deal before the Spring 2027 RTP funding window opens. If they miss that window, they risk missing the wave of accelerated cash deployment before the RTP program ends in December 2027.
- ·2 päivää sitten-98.68% overall I am selling out and taking my loss, all trust in this company is gone Watch out out there with falling knives especially this one
- ·26.10.How are you?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 000 | ||
| 10 000 | ||
| 10 000 | ||
| 10 000 | ||
| 10 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt